Table 3.

Additional treatment in CXCL13- high and CXCL13- low group

	DMARD + ADA		DMARD
	CXCL13- high	CXCL13- low	CXCL13- high	CXCL13- low
Additional treatment	6/27, 22.2%	4/10, 40%	9/23, 39,1%	6/16, 37,5%

Number of patients in the CXCL13-high and -low group treated with additional DMARDs than MTX. If sulphasalazine, hydroxychloroquine or both has been added to the treatment during the 2-year follow-up patients will be considered to be receiving additional treatment. x/y represents the number of patients receiving additional treatment/number of patients in the group. ADA: adalimumab; CXCR13: C-X-C chemokine receptor type 13; DMARD: disease-modifying anti-rheumatic drug.